Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Renal Transplantation in Jehovah’s Witnesses: A Single-Center Experience
J. Rao, A. Matas, S. Jackson, V. Humphreville
Transplant Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Transplant in Jehovah's Witnesses (JW) has been controversial due to their religious beliefs resulting in frequent refusal to accept a wide range of blood…
2020 American Transplant Congress
Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
M. Okada¹, T. Tomosugi¹, T. Hiramitsu¹, S. Narumi¹, Y. Watarai¹, A. Kanda¹, K. Futamura¹, N. Goto¹, A. Takeda²
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan, ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
*Purpose: De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact…
2020 American Transplant Congress
Application of Diffusional Kurtosis Imaging for Non-Invasive Assessment of Chronic Allograft Injury
Y. Xu¹, X. Zheng², H. Liu¹, X. Hu¹
¹Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Urology Institute of Capital Medical University, Beijing, China, ²Urology Department, Beijing YouAn Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the feasibility and clinical application of diffusional kurtosis imaging (DKI) technique in non-invasive assessment for chronic allograft injury (CAI).*Methods: The local ethics…
2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
V. R. Peddi¹, B. Marder², L. Gaite³, J. Oberholzer⁴, R. Goldberg⁵, T. Pearson⁶, H. Yang⁷, L. Allamassey⁸, S. Gao⁸, M. Polinsky⁸, R. N. Formica⁹
¹California Pacific Medical Center, San Francisco, CA, ²Colorado Kidney Care, Denver, CO, ³Hospital Marqués de Valdecilla, Cantabria, Spain, ⁴UVA Health, Charlottesville, VA, ⁵Saint Barnabas Medical Center, Livingston, NJ, ⁶Emory University School of Medicine, Atlanta, GA, ⁷UPMC Pinnacle, Harrisburg, PA, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Yale University School of Medicine, New Haven, CT
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
2020 American Transplant Congress
Outcome after Kidney Transplantation in Hepatitis Surface Antigen-Positive Patients
H. Mo, S. Min, H. Ko, C. Chung, H. Kim, A. Han, J. Ha
Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Because of the low prevalence of Hepatitis Surface Antigen (HBsAg)-positive patients, only a few reports have evaluated the actual outcome of these patients after…
2020 American Transplant Congress
Morbid Obesity: A Growing Barrier to Early Kidney Transplant Wait-Listing in the United States
L. Lavenburg¹, E. Weinhandl², L. Robinson³, B. Milliron⁴, C. Earthman⁵, A. Klassen³, M. Harhay⁶
¹University of Pennsylvania, Philadelphia, PA, ²Fresenius Medical Care North America, Minneapolis, MN, ³Drexel University Dornsife School of Public Health, Philadelphia, PA, ⁴Drexel University College of Nursing and Health Professions, Philadelphia, PA, ⁵University of Delaware, Newark, DE, ⁶Drexel University College of Medicine, Philadelphia, PA
*Purpose: Kidney transplant (KT) programs may be more reluctant to accept transplant candidates with morbid obesity due to concerns about higher post-operative risks. We examined…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
R. Craig-Schapiro, B. Magaoay, R. Grover, S. Sultan, M. Aull, S. Kapur
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…
2020 American Transplant Congress
The Impact of Increased Visceral Fat in Kidney Transplant Recipients
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
Ehime University, Toon, Japan
*Purpose: An increased amount of visceral fat (VF) has been reported as a precursor to metabolic syndrome and is a risk factor for renal dysfunction.…
2020 American Transplant Congress
Long-Term Outcome of Kidney Transplantation for IgA Nephropathy: A Single-Center Experiences
M. Tasaki¹, K. Saito¹, Y. Nakagawa², N. Imai³, Y. Ito³, K. Takahashi⁴, Y. Tomita¹
¹Division of Urology, Department of Regenerative & Transplant, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Division of Urology, Juntendo University, Tokyo, Japan, ³Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ⁴Otsukadai Clinic, Tokyo, Japan
*Purpose: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation (KTx). The aim of this…